NuCana plc (NCNA) stock
NCNANasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.83−0.06 (-6.42%)
Close on Nov 18, 2026Market cap $3.47MP/E –Yield –
NuCana operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
NuCana's operating income for the twelve months ending Dec 31, 2021 was -£47.91M. For fiscal 2025 it was -£20.11M. The highest annual figure on record is -£6.91M in fiscal 2015.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -£20.11M | – |
| FY2024 | Dec 31, 2024 | -£22.81M | – |
| FY2023 | Dec 31, 2023 | -£32.78M | – |
| FY2022 | Dec 31, 2022 | -£39.12M | – |
| FY2021 | Dec 31, 2021 | -£47.91M | – |
| FY2020 | Dec 31, 2020 | -£36.42M | – |
| FY2019 | Dec 31, 2019 | -£26.70M | – |
| FY2018 | Dec 31, 2018 | -£19.13M | – |
| FY2017 | Dec 31, 2017 | -£25.69M | – |
| FY2016 | Dec 31, 2016 | -£8.45M | – |
| FY2015 | Dec 31, 2015 | -£6.91M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -£3.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -£11.83M | – |
| Q2 FY2024 | Jun 30, 2024 | -£8.35M | – |
| Q2 FY2023 | Jun 30, 2023 | -£6.28M | – |
| Q2 FY2022 | Jun 30, 2022 | -£5.22M | – |
| Q4 FY2021 | Dec 31, 2021 | -£15.74M | – |
| Q3 FY2021 | Sep 30, 2021 | -£9.97M | – |
| Q2 FY2021 | Jun 30, 2021 | -£10.71M | – |
| Q1 FY2021 | Mar 31, 2021 | -£11.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -£13.97M | – |
| Q3 FY2020 | Sep 30, 2020 | -£9.62M | – |
| Q2 FY2020 | Jun 30, 2020 | -£7.41M | – |
| Q1 FY2020 | Mar 31, 2020 | -£5.42M | – |
| Q4 FY2019 | Dec 31, 2019 | -£9.11M | – |
| Q3 FY2019 | Sep 30, 2019 | -£5.04M | – |
| Q2 FY2019 | Jun 30, 2019 | -£5.88M | – |
| Q1 FY2019 | Mar 31, 2019 | -£6.68M | – |
| Q4 FY2018 | Dec 31, 2018 | -£5.10M | – |
| Q3 FY2018 | Sep 30, 2018 | -£3.58M | – |
| Q2 FY2018 | Jun 30, 2018 | -£2.95M | – |
| Q1 FY2018 | Mar 31, 2018 | -£7.49M | – |
| Q4 FY2017 | Dec 31, 2017 | -£5.87M | – |
| Q3 FY2017 | Sep 30, 2017 | -£14.27M | – |
| Q2 FY2017 | Jun 30, 2017 | -£3.54M | – |
See a number that looks wrong?